Stockreport

Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress [Yahoo! Finance]

Zenas BioPharma, Inc.  (ZBIO) 
PDF Zenas BioPharma started trading on the NASDAQ in September 2024. The company closed an upsized initial public offering of 15.22 million shares at $17 per share, raising [Read more]